Longenesis was established in 2019 with a clear goal – to transform a traditional process of conducting biomedical research. They have developed a tool for identification of stakeholders for further collaboration, SaaS digital patient consent management tool and disease-specific tools for patients/population cohorts proactive engagement in clinical research activities. In just 3 years of existence, the company has initiated a collaboration with 20+ biomedical institutions, as well as patient organizations, biobanks, genomic sequencers, clinics and health authorities in the U.S., South Korea, Northern European region, and the Middle East.